Also known as: Penn
Recent studies show microbiome modulation boosts chemotherapy accumulation, peptide-based mRNA vaccines shrink neuroblastoma tumors by 70%, and engineered LNPs enhance lymph node delivery while cutting side effects.
Penn joined 35 universities in an amicus brief supporting Harvard’s lawsuit against a $2 billion federal research funding freeze. The brief warns that such cuts endanger basic research and innovation, as Penn itself faces over $400 million in recent funding freezes and cuts.
A U.S. appeals court revived Regenxbio’s patent suit against Sarepta, holding the asserted gene-therapy host cell claims are markedly different from anything occurring in nature.
Pitt received $669.7 million in NIH funding in 2025 to rank No. 7 nationally. Penn Nursing received $17.9 million, ranking first among U.S. nursing schools.
Congress rejected the administration’s deepest proposed science cuts, increasing NIH funding by about $415 million to $48.7 billion. NASA and NSF also saw far smaller reductions than proposed.
Wafik S. El-Deiry highlighted p53 research and the August 2025 approval of dordaviprone/modeyso, the first treatment for diffuse gliomas with H3K27M mutations. Separate posts also described glioblastoma precision oncology discussions and a lifetime achievement award in Mumbai.
Ultragenyx received FDA clearance for UX016 in GNE myopathy, with a Phase 1/2 study planned for 2026. Soligenix's confirmatory HyBryte trial for CTCL has 66 of 80 patients enrolled, and an interim analysis is expected in early 2026.
New AI-powered platforms enable same-day cancer treatment decisions and streamline clinical trial matching. University of Utah's μPharma chip predicts drug responses in under four hours, while City of Hope's HopeLLM system matches patients to trials across its national network.
The FDA has established a "plausible mechanism pathway" to approve personalized genome editing and RNA-based therapies for rare and ultra-rare diseases without requiring large randomized controlled trials, streamlining access to individualized treatments.
Recent publications and collaborations advance glioblastoma research through blood-based microRNA diagnostics, combination immunotherapy trials, and identification of MOV10 as a prognostic biomarker and therapeutic target.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779642 |
Precision Medicine Adaptive Network Platform Trial in Hypoxemic Acute Respiratory Failure |
NOT_YET_RECRUITING | PHASE2 |
| NCT07777926 |
Evaluation of Filler Injection for Chin Profile Enhancement |
RECRUITING | PHASE4 |
| NCT07773753 |
Validation of the Vision Trainer Clinical Decision-Support Software |
NOT_YET_RECRUITING | NA |
| NCT07766694 |
Evaluating the Preferences and Tradeoffs of AI-based Electronic Consultations for Older Adults in Primary Care |
NOT_YET_RECRUITING | NA |
| NCT07756424 |
Implementation of a Disparities in Labor Outcomes Dashboard |
NOT_YET_RECRUITING | NA |
| NCT07752576 |
Designing and Evaluating Multi-level Implementation Strategies to Address Alcohol Use Within Oncology Care |
NOT_YET_RECRUITING | NA |
| NCT07738874 |
Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care |
NOT_YET_RECRUITING | NA |
| NCT07735286 |
Automating Tobacco Cessation in Primary Care |
NOT_YET_RECRUITING | NA |
| NCT07728994 |
SONATA LIFU for OCD |
RECRUITING | PHASE2 |
| NCT07703891 |
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa |
NOT_YET_RECRUITING | NA |
